Simultaneous analysis of eprosartan and hydrochlorothiazide in tablets by high-performance thin-layer chromatography with ultraviolet absorption densitometry

• Autorzy: Patel H. U. , Suhagia B. N , Patel C. N.
• Języki publikacji: EN

Abstrakty

EN

A new, simple, accurate, and precise high-performance thin-layer chromatographic (HPTLC) method has been established for simultaneous analysis of eprosartan and hydrochlorothiazide in tablet formulations. Standard and sample solutions of eprosartan and hydrochlorothiazide were applied to precoated silica gel G 60 F 254 HPTLC plates and the plates were developed with benzene-methanol-formic acid 7:3:0.1 ( υ/υ ) as mobile phase. Detection and evaluation of chromatograms was performed densitometrically at 272 nm. The retention factors of eprosartan and hydrochlorothiazide were 0.76 and 0.57, respectively. The linear range was 4.8–43.2 μg per spot for eprosartan and 0.15–1.35 μg per spot for hydrochlorothiazide; the correlation coefficients, r , were 0.998 and 0.999, respectively. The method was validated and successfully used for analysis of the drugs in tablets.

Słowa kluczowe

EN

HPTLC; eprosartan; hydrochlorothiazide; tablets; validation

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2009
• Tom: Vol. 21, no. 2
• Strony: 319--326
• Opis fizyczny: Bibliogr. 18 poz., rys., tab.

Twórcy

autor

Patel H. U.

• Shri Sarvajanik Pharmacy College Department of Pharmaceutical Chemistry Near Arvind Baug Mehsana 384001 Gujarat India

autor

Suhagia B. N

• L.M. College of Pharmacy Department of Pharmaceutical Chemistry Navrangpura, Ahmedabad 380009 Gujarat India

autor

Patel C. N.

• Shri Sarvajanik Pharmacy College Department of Pharmaceutical Chemistry Near Arvind Baug Mehsana 384001 Gujarat India

Bibliografia

• [1] K.J. McClellan and J. A. Balfour, Drugs, 55 , 713 (1998)
• [2] The Merck Index — An Encyclopedia of Chemicals, Drugs and Biologicals, 13th edn, Merck, USA, 2001, p. 1692
• [3] P.A. Meredith, Am. J. Cardiovasc. Drugs, 5 , 171 (2005)
• [4] F. Nerea, D. Sebastian, A.R. Maria, and W. Wolfgang, Ther. Drug Monit., 29 , 824 (2007)
• [5] S. Hillaert and W.V. Bossche, J. Chromatogr. B, 977 , 323 (2002)
• [6] S. Hillaert, T.R.M. De Beer, J.O. De Beer, and W.V. Bossche, J. Chromatogr. A, 984 , 135 (2003)
• [7] D.E. Lundberg, C. Renee Person, S. Knox, and M.J. Cyronak, J. Chromatogr. B, 707 , 328 (1998)
• [8] N. Ferreirós, G. Iriarte, R.M. Alonso, and R.M. Jiménez, Talanta, 69 , 747 (2006)
• [9] S. Mariusz, A. Maslanka, and K. Jan, J. Liq. Chromatogr. Related Technol., 31 , 1892 (2008)
• [10] T. Mingtao and Y. Xiangan, Zhongguo Yaofang, 19 , 543 (2008)
• [11] S. Eda, A. Sadi, G.G. Nilgun, A.O. Sibel, and S. Zuhre, J. Pharm. Biomed. Anal., 25 , 1009 (2001)
• [12] I.B. Lories, S.A. Samah, A.F. Laila, and H.R. Heba, Farmaco II, 60 , 859 (2005)
• [13] O. Sagirli, A. Onal, S.E. Toker, and D. Sensoy, Chromatographia, 66 , 213 (2007)
• [14] ICH Guidelines Q2B, Validation of Analytical Procedures — Methodology, 1996
• [15] FDA-CDER (CMC 3), Reviewer Guidance, Validation of Chromatographic Methods, November, 1994
• [16] E. Heftman, Chromatography — Fundamentals and Applications of Chromatography and Related Differential Migration Methods, Vol. 69A, 6th edn, Elsevier, Amsterdam, 2004, pp. 253–291
• [17] J. Cazes and R.P.W. Scott, Chromatography Theory, Marcel Dekker, NY, 2002, pp. 443–454
• [18] P.D. Sethi, HPTLC: Quantitative Analysis of Pharmaceutical Formulations, CBS Publications, New Delhi, 1996, pp. 162–165